XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
  Anti-Inflammatory
  Antivirals
  Antihypertensives
  Anticholesterol
  Anti-Clotting Drugs
  Anti Cancer Drugs
  Hypnotics
  PPI
  Antibiotics
  Analgesics
  Surfactants
  Fatty Acids
  Adrenergics
  Metals
  Varenicline
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Nov 17th, 2006 - 22:35:04

Pharmacology Channel
subscribe to Pharmacology newsletter

Latest Research : Pharmacology

   DISCUSS   |   EMAIL   |   PRINT
Over The Counter Topical Progesterone Raises Concern
Jul 17, 2005, 09:48, Reviewed by: Dr.

Given the risks associated with prolonged progesterone therapy, the researchers note with concern that women may be exposing themselves to similar risks without the counseling, screening and supervision that accompany the use of prescription products.

 
There has been considerable concern about the risk that many over-the counter (OTC) cosmetic preparations may pose to the public, since many of these are not regulated by the FDA and are commonly used without medical supervision. Progesterone, which is commonly prescribed in women, is often used in hormone replacement therapy in postmenopausal women, and for the treatment of amenorrhea, infertility and premature labor. Past studies revealing the health risks of FDA-approved hormone replacement therapy (including oral progesterones and progestins) have contributed to dramatic declines in prescriptions for these products. However, unregulated natural progesterone continues to be sold over-the-counter in the form of herbal beauty creams, thus exempting them from regulatory scrutiny.

In a study recently published in The Journal of Clinical Pharmacology, ( June 2005 ) researchers found substantial evidence that use of OTC topical progesterone results in similar drug exposure through skin absorption as that which results from taking a prescribed oral progesterone product.

The Bassett Healthcare supported study, led by Drs. Anne C. Hermann, Anne Nafziger and Joseph Bertino, consisted of twelve, healthy, post-menopausal women. Each subject was treated with topical OTC progesterone ( Pro-gest cream ) in one phase and prescribed oral progesterone ( Prometrium ) in the other phase of the study.

According to the results, there was no difference between the two groups in the amount of progesterone exposure in the body. The women involved in this study also experienced similar rates of adverse effects while taking each type of progesterone. This study differed from previous studies because of its use of more precise and advanced drug analysis methods, giving results that are accurate compared to previous studies with topical progesterone products.

Given the risks associated with prolonged progesterone therapy, the researchers note with concern that women may be exposing themselves to similar risks without the counseling, screening and supervision that accompany the use of prescription products.
 

- The study is published in The Journal of Clinical Pharmacology, ( June 2005 )
 

American College of Clinical Pharmacology

 
Subscribe to Pharmacology Newsletter
E-mail Address:

 

This study was supported by a grant from the E. Donnall Thomas resident research fund, Bassett Healthcare, Cooperstown, New York. The article "Over-the-Counter Progesterone Cream Produces Significant Drug Exposure Compared to a Food and Drug Administration-Approved Oral Progesterone Product" can be found on The Journal of Clinical Pharmacology web site at www.jclinpharm.org. Media may receive a free copy of the article by contacting Valerie Johns at SAGE Publications via email at [email protected].

About The Journal of Clinical Pharmacology

For over 45 years, clinical pharmacologists, clinical and pharmaceutical researchers, drug development specialists, physicians, nurses, and other medical professionals have relied on The Journal of Clinical Pharmacology for original research, special reviews, commentaries, and case reports on all phases of drug development. One of the most highly cited journals in the field, it features up to-the-minute and pertinent clinical information about the safety, tolerability, efficacy, therapeutic applications, toxicology, and total evaluation of new and established drugs for humans. JCP is the official journal for the American College of Clinical Pharmacology ( http://.accp1.org ).

About SAGE:

SAGE Publications ( http://www.sagepublications.com ) is a leading international publisher of journals, books, and electronic media for academic, educational, and professional markets. Since 1965, SAGE has helped inform and educate a global community of scholars, practitioners, researchers, and students. SAGE Publications, a privately owned corporation, has principal offices in Thousand Oaks, California, London, United Kingdom, and in New Delhi, India.

SAGE Publications
http://www.sagepub.com


Related Pharmacology News

Phase Ib Trial Is Evaluating Bavituximab Administered With Common Chemotherapy Regimens
Two-component lantibiotic with therapeutic potential discovered
Prescription pain medication abuse on rise
Antibiotic inhibits cancer gene activity
NRTIs limits the atherogenic side effect of the protease inhibitors
Cyclin-dependent kinase inhibitors: The latest anti-inflammatory
FDA requested to promptly approve 17-P to prevent premature birth
Rapamycin shown to inhibit angiogenesis
Tigecycline, world�s first glycylcycline expanded broad-spectrum antibiotic, launched in UK
Ibuprofen - worsening cognitive function


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us